STOCK TITAN

United Therapeutics (UTHR) grants director Victor Dzau RSUs and stock options

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

United Therapeutics Corporation director Victor J. Dzau reported equity awards received on July 22, 2026 in connection with his appointment to the Board. He was granted 730 restricted stock units and 2,300 stock options under the Non-Employee Director Compensation Program. Each RSU represents one share of common stock upon vesting. The stock options cover common stock at an exercise price of $527.0700 per share, vest on the one-year anniversary of the grant date, and expire on July 22, 2033.

Positive

  • None.

Negative

  • None.
Insider DZAU VICTOR J
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit F1, F2, F3 730 $0.00 $0.00
Grant/Award Stock Option F2 2,300 $0.00 $0.00
Holdings After Transaction: Restricted Stock Unit — 730 shares (Direct); Stock Option — 2,300 shares (Direct)
Footnotes (3)
  1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
  2. F2. In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date.
  3. F3. Not applicable as restricted stock units do not have an expiration date.
Restricted Stock Units Granted 730 units Equity awards to Victor J. Dzau on July 22, 2026
Stock Options Granted 2,300 options Equity awards to Victor J. Dzau on July 22, 2026
Stock Option Exercise Price $527.0700 per share Exercise price for 2,300 stock options granted July 22, 2026
Vesting Timing One-year anniversary of grant date Each award becomes fully vested one year after July 22, 2026
Option Expiration Date July 22, 2033 Expiration of stock options granted to Victor J. Dzau
Restricted Stock Unit financial
"Each restricted stock unit represents the right to receive, following vesting, one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Stock Option financial
"he was awarded restricted stock units and stock options in accordance with the program"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
Non-Employee Director Compensation Program financial
"awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program"
exercise price financial
"Stock Option transaction shows an exercise price of 527.0700 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"Each award becomes fully vests on the one-year anniversary of the grant date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did United Therapeutics (UTHR) report for Victor J. Dzau?

United Therapeutics reported that director Victor J. Dzau received equity awards on July 22, 2026. He was granted 730 restricted stock units and 2,300 stock options in connection with his appointment to the Board under the Non-Employee Director Compensation Program.

How many restricted stock units did Victor J. Dzau receive from UTHR?

Victor J. Dzau received 730 restricted stock units from United Therapeutics. Each restricted stock unit represents the right to receive one share of United Therapeutics common stock after the units vest on the one-year anniversary of the July 22, 2026 grant date.

What stock options were granted to Victor J. Dzau by United Therapeutics (UTHR)?

Victor J. Dzau was granted 2,300 stock options for United Therapeutics common stock. The options have an exercise price of $527.0700 per share, vest on the one-year anniversary of the July 22, 2026 grant date, and expire on July 22, 2033.

How are Victor J. Dzau’s UTHR equity awards structured between initial and pro-rata grants?

Victor J. Dzau’s awards include an initial grant of 380 RSUs and 1,190 options, plus pro-rata grants of 350 RSUs and 1,110 options. These pro-rata grants represent the remainder of the 2026–2027 Board service year under the Non-Employee Director Compensation Program.

When do Victor J. Dzau’s United Therapeutics (UTHR) director awards vest and expire?

Both the restricted stock units and stock options awarded to Victor J. Dzau fully vest one year after the July 22, 2026 grant date. The stock options then remain exercisable until their stated expiration on July 22, 2033; the RSUs do not have an expiration date.

Were Victor J. Dzau’s UTHR equity grants made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not affirmatively marked for these transactions. The awards are described as grants made under the Non-Employee Director Compensation Program in connection with his appointment to the United Therapeutics Board.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DZAU VICTOR J

(Last)(First)(Middle)
C/O UNITED THERAPEUTICS CORPORATION
1000 SPRING STREET

(Street)
SILVER SPRING MARYLAND 20910

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit$0.00(1)07/22/2026A730(2)07/22/2027 (3)Common Stock730$0.00730D
Stock Option$527.0707/22/2026A2,300(2)07/22/202707/22/2033Common Stock2,300$0.002,300D
Explanation of Responses:
1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. In connection with Dr. Dzau's appointment to the Board of Directors on July 22, 2026, he was awarded restricted stock units and stock options in accordance with the Non-Employee Director Compensation Program, as follows: (a) 380 restricted stock units and 1,190 stock options, representing his initial grant upon joining the Board, and (b) 350 restricted stock units and 1,110 stock options, which are pro-rata grants representing the remainder of the 2026-2027 Board service year. Each award becomes fully vests on the one-year anniversary of the grant date.
3. Not applicable as restricted stock units do not have an expiration date.
Remarks:
/s/ John S. Hess, Jr. under Power of Attorney07/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)